This document discusses using evidence-based marketing to maximize the impact of an integrated unbranded marketing campaign. It describes a 4-phase project conducted by Gilead Sciences to develop a patient marketing platform for angina. Phase 1 involved analyzing the competitive landscape. Phase 2 identified 3 patient segments through research. Phase 3 developed targeted communication streams. Phase 4 integrated HCP and patient marketing efforts to drive growth through an action cascade. Early metrics showed the campaign addressed an unmet need and drove engagement.
Health Industry & Content Marketing: Takeaways from the 2014 Content Marketin...MSL
This infographic shares key takeaways from the 2014 Content Marketing for Life Sciences Conference to help the health industry further enhance content marketing practices.
Two or three years ago, content marketing was a novel concept in communications. But this year, content programs are more prevalent in our industry than in the prior year.
Content this year is largely unbranded, very visual, and filled with inspiring
patient-focused storytelling. Whether pharma, healthcare systems or devices and diagnostics – all kinds of organizations in health have found their way in the world of content marketing.
Most communication programs are oriented to patients or consumers and some to healthcare providers. Content marketing for life sciences now offers an engaging and educational way to be a more informed consumer of health information and to help HCPs take action that will help improve their own or their patients’ lives.
MSLGROUP hosted the second year of Content Marketing for Life Sciences Conference in Philadelphia, PA.
Corporations and global brands have found adopting social media a challenge. Most have turned a blind eye often siting the excuse 'there's too much regulation around our industry to get involved'. This presentation covers 3 pharmaceutical brands who have jumped in the deep end and done it. The results are surprising and deeply insightful on what happened and what were the results.
Health Industry & Content Marketing: Takeaways from the 2014 Content Marketin...MSL
This infographic shares key takeaways from the 2014 Content Marketing for Life Sciences Conference to help the health industry further enhance content marketing practices.
Two or three years ago, content marketing was a novel concept in communications. But this year, content programs are more prevalent in our industry than in the prior year.
Content this year is largely unbranded, very visual, and filled with inspiring
patient-focused storytelling. Whether pharma, healthcare systems or devices and diagnostics – all kinds of organizations in health have found their way in the world of content marketing.
Most communication programs are oriented to patients or consumers and some to healthcare providers. Content marketing for life sciences now offers an engaging and educational way to be a more informed consumer of health information and to help HCPs take action that will help improve their own or their patients’ lives.
MSLGROUP hosted the second year of Content Marketing for Life Sciences Conference in Philadelphia, PA.
Corporations and global brands have found adopting social media a challenge. Most have turned a blind eye often siting the excuse 'there's too much regulation around our industry to get involved'. This presentation covers 3 pharmaceutical brands who have jumped in the deep end and done it. The results are surprising and deeply insightful on what happened and what were the results.
Redefining the role of patient support programs: Shifting the focus towards p...SKIM
Presented by:
Alex Zhu, Manager
Ariel Herrlich, Analyst
The recent shift toward consumerism and patient empowerment is driving companies to reevaluate the role and design of patient support programs. Historically, pharmaceutical manufacturers implemented support programs largely as a way to address patient non-adherence.
These programs were often single-based solutions designed to meet mass market needs. Next generation patient support programs will go beyond simple adherence to address holistic disease management through individualized, patient-centric service offerings.
Using a case study, we illustrated:
- How to evaluate your current patient support program offerings, using a combination of standard and non-standard metrics and exercises
- Re-define what “value” means in a world of patient-centricity and personalized care
- Assess the impact/ROI of potential new service offerings and enhancements
The basics of launching a pharmaceutical drug-
Based on studies done on the practices of 13 top pharmaceutical companies in the world.
For more, write to info@markivmedical.com
Walzer Case Study Launching And Selling A Pharmaceutical Compound With The Pa...walzer_18
The importance of the health care payer view in the development of a new compund is exemplarily shown and was presented at a conference in London in March 2012
SKIMspiration2012: Creative Lab | Nutricia case studySKIM
Being close to your local target group is crucial for every business. However, brands nowadays mostly only survive with convincing global communication strategies. Aligning these different perspectives is a challenge. SKIM's Creative Lab approach combines a new mindset with an effective approach to communication testing, which has proved successful in helping global and local marketers to jointly create and support the future communication strategy. Eva and Henrike showed us how Nutricia and SKIM made it happen!
Redefining the role of patient support programs: Shifting the focus towards p...SKIM
Presented by:
Alex Zhu, Manager
Ariel Herrlich, Analyst
The recent shift toward consumerism and patient empowerment is driving companies to reevaluate the role and design of patient support programs. Historically, pharmaceutical manufacturers implemented support programs largely as a way to address patient non-adherence.
These programs were often single-based solutions designed to meet mass market needs. Next generation patient support programs will go beyond simple adherence to address holistic disease management through individualized, patient-centric service offerings.
Using a case study, we illustrated:
- How to evaluate your current patient support program offerings, using a combination of standard and non-standard metrics and exercises
- Re-define what “value” means in a world of patient-centricity and personalized care
- Assess the impact/ROI of potential new service offerings and enhancements
The basics of launching a pharmaceutical drug-
Based on studies done on the practices of 13 top pharmaceutical companies in the world.
For more, write to info@markivmedical.com
Walzer Case Study Launching And Selling A Pharmaceutical Compound With The Pa...walzer_18
The importance of the health care payer view in the development of a new compund is exemplarily shown and was presented at a conference in London in March 2012
SKIMspiration2012: Creative Lab | Nutricia case studySKIM
Being close to your local target group is crucial for every business. However, brands nowadays mostly only survive with convincing global communication strategies. Aligning these different perspectives is a challenge. SKIM's Creative Lab approach combines a new mindset with an effective approach to communication testing, which has proved successful in helping global and local marketers to jointly create and support the future communication strategy. Eva and Henrike showed us how Nutricia and SKIM made it happen!
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
CDSCO and Phamacovigilance {Regulatory body in India}
Using Evidence-Based Marketing to Maximize the Impact of an Integrated Unbranded Campaign
1. Using Evidence-Based Marketing to Maximize the
Impact of an Integrated Unbranded Campaign
Tina Sampath Kirsten York
Associate Director, Patient Evidence-Based Marketing
Marketing & HCP eMarketing Practice Lead
Gilead Sciences Return on Focus, LLC
2. Evidence-Based Marketing Approach
Marketing Evidence Influence
Identify a Do the right Maximize the
marketing research and impact of the
opportunity do it well execution
3. Patient Marketing Platform Project: Phase 1
Q4 2008/Q1 2009 Q4 2009 Q1 2010 Q1 2010
Phase 1
Phase 1 Phase 2 Phase 3 Phase 4
Competitive Landscape
Competitive Landscape Patient Segmentation Communication Platform HCP/Patient Integrated
Appraisal
Analysis (Qual/Quant) Development & Testing Action Cascade
Phase 1 Key Strategic Questions:
• What are related therapies doing?
• Where are there gaps in the available
information set (gaps = opportunities)?
• What are the “Must Haves”?
5
4. Phase 1 Consumer Landscape Analysis
Key Observations
OBSERVATION OPPORTUNITY
There is a lack of unbranded Develop an unbranded
disease content that is patient education site to
specific to angina. drive acquisition.
Explore opportunities to
Competitive set is
evaluate impact of
establishing an expectation
integrating interactive video
of significant video content.
and some personalization.
Competitive set is actively Explore opportunities to
engaging key CV advocacy partner with PCNA, Mended
organizations. Hearts and Women Heart.
6
5. Patient Marketing Platform Project:
Phase 2
Q4 2008/Q1 2009 Q4 2009 Q1 2010 Q1 2010
Phase 1 Phase 2
Phase 2 Phase 3 Phase 4
Competitive Landscape Patient Segmentation
Patient Segmentation Communication Platform HCP/Patient Integrated
Appraisal Study
(Qual/Quant) Development & Testing Action Cascade
Phase 2 Key Strategic Questions:
• Are there distinct attitudinal segments within
the angina population?
• Who are the patients most receptive to
marketing efforts?
7
6. Three Distinct Patient Segments
Identified (N=500 Chronic Angina Sufferers)
OPTIMISTIC BURDENED
N=196 N=172
DISTRUSTFUL
N=132
Segment membership is readily
determined with 82% accuracy
via a validated 5-question
predictive model
7. Unmet Need:
Disease State Education
of the patients believed they
received no explanation about
angina when they were diagnosed
of patients fear they might be
76% having a heart attack when they
have angina
10
8. Patient Marketing Platform Project: Phase 3
Q4 2008/Q1 2009 Q4 2009 Q1 2010 Q2 2010
Phase 1 Phase 2 Phase 3 Phase 4
Competitive Landscape Patient Segmentation Communication Platform
Communication Platform HCP/Patient Integrated
Appraisal (Qual/Quant) Development & Testing
Development Action Cascade
Unbranded
Campaign Unbranded Campaign Development
Concepting
Phase 3 Key Strategic Question:
• Now that we know who our target patients are,
what are we going to say to them?
11
9. 3 Distinct
Communication Streams
Burdened Patients:
Educate and empower discussion with Cardiologist about negative
impact of angina on physical activity and emotional well-being
Optimistic Patients:
Encourage self-realization and subsequent discussion with
Cardiologist about the potential to do even more to control
ongoing attacks and continue living well with angina
Unsegmented
If your angina is being managed and yet you continue to have attacks on a
regular basis, it’s time to have a heart-to-heart with your Cardiologist.
12. Patient Marketing Platform Project:
Unbranded Campaign Development, Phase 4
Q4 2008/Q1 2009 Q4 2009 Q1 2010 Q2 2010
Phase 1 Phase 2 Phase 3 Phase 4
Competitive Landscape Patient Segmentation Communication Platform HCP/Patient Integrated
HCP/Patient Integrated
Appraisal (Qual/Quant) Development Action Cascade
Action Cascade
Unbranded
Campaign Unbranded Campaign Development
Concepting
Phase 4 Key Strategic Question:
• How do all of our HCP & patient marketing
efforts integrate to drive growth?
15
13. The Disconnect Confirmed
• Physicians overestimate patient satisfaction with
QOL, underestimate extent to which patients are
limiting or giving up activities
80%
70%
69%
60%
50% 56%
53% HCP
40% 43% Patients
39%
30%
20% 27%
22%
10% 13%
0%
Able to Content with Avoid activities that Have given up most
enjoy life overall QOL May cause angina Activities due to angina
Sources:
1. Data on file. Q2 Physician ATU (N=194: Cardiologists=122, Other Specialty= 52) Prepared by Harris Interactive. July 12, 2010.
2. Data on file. Chronic Angina Patient Segmentation Study (N=500). Prepared by Return on Focus, LLC. January 4, 2010.
16
14. Validated Action Cascade for
Unbranded and Branded Campaigns
Angina patient is exposed to Continuing attacks
Patient unbranded materials online or
Increased frequency of attacks
in-office and initiates
Unbranded discussion with CARD Worsening in attack severity
Ongoing impact on QOL
Side effects from current therapy
CARD listens for catalysts
compelling treatment change
CARD pre-selects
appropriate patients
RX and writes script for
only a % of the
eligible pool
HCP Drives patient
Unbranded selection &
pull-through
SFTH materials rolled Branded patient
out to office support Patient requests will be Professional
staff could ultimately honored by CARD
Branded Branded
influence receptivity to
patient discussion
Segment-specific messaging
to drive brand adherence
17
16. Early Metrics: First 3 Months
• Mended Hearts Summer
2010 Heartbeat
“Recently Mended Hearts joined PCNA and partnered with
– Cover story inspired by
Gilead Sciences to promote “Speak From the Heart,”
SFTH campaign
a public awareness campaign focused on communicating
– Heartbeat distribution:
with 20K+ cardiologist aboutheart
your households with angina.”
disease + 200K patients
annually
– Interview with
Kathy Berra, RN, NP,
Clinical Director, Stanford
Heart Network
– SFTH sidebar story
19
17
17. Further Validation that Speak From the Heart
Addresses an Unmet Need- Metrics Thru 9/9
• SpeakFromTheHeart.com (Launch date 5/17/2010):
– Visits: 18,339 (5/17 - 9/9)
– Page Views: 44,247 (5/17 - 9/9)
– Most popular content:
• Self Assessment 7450 views
• What is Angina? 6346 views
• Patient Videos 4084 views
• Reducing Symptoms 4874 views
• Angina Animation 2029 views
• Digital Media (7/7 - 8/31)
– Impressions: 5,757,690
– Media spend to date: $75,869
– Above industry average click thru rated (CTRs)**
• WebMD: .53% (Over 8x industry average)
• Everyday Health: .20% (Over 3x industry average)
• MedHelp: .21% (Over 3x industry average)
• Mayo Clinic: .17% (Nearly 3x industry average)
Sources: Nielsen
1. *Industry average time on site for unbranded campaigns with rich content= 4 minutes
2. **Industry average CTR = .06%
20